The evaluation of Velmanase alfa for treating alpha-mannosidosis has been put on hold.
This HST evaluation has been put on hold as of 2 October 2018. The company which markets this technology (Chiesi) are currently developing an offering for submission to NHS England. Once confirmation of the submission has been received NICE will be in a position to provide a further update on timelines in order to progress the HST evaluation.
Updates on the next steps will available in due course. For more information visit the NICE website.
If you have any queries please email email@example.com
If you want to discuss this with one of our Advocacy Support Team please get in touch.
More information about alpha-mannosidosis is available here.